Overall, these results suggest that MEOX2 and GLI-1 play divergent roles in lung cancer progression, and response to EGFR-TKIs-based therapy, with both MEOX2/GLI-1 potentially influencing EGFR gene expression. The gene discussed is EGFR; the disease is lung carcinoma.